Gitnux/Report 2026

Medicine Business Industry Statistics

The global pharmaceutical market reached an estimated $1.225 trillion in 2025, explore the medicine business figures on growth, companies and trends.
61Statistics
43Sources
10Sections
1Visuals
22mRead
Medicine Business Industry Statistics
How this report is researched
01Editorial Scope

Gitnux editors write the brief first: the topic, the inclusion rules, and the frame for what belongs.

02Source Research

Agents search the published record and log every extracted figure back to the passage it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 38 days

01 Industry overview

The medicine business industry at a glance

The global pharmaceutical market reached an estimated $1.225 trillion in 2025, with North America accounting for 54.7% of worldwide prescription-medicine sales and continued growth driven by specialty medicines and obesity treatments.

$1.225T[28]
Global market sales, 2025
5–8%[29]
Medicine spending growth to 2030
54.7%[30]
North America sales share, 2025
46[31]
FDA novel drugs approved, 2025
Market size
The global pharmaceutical market generated estimated reported sales of $1.225 trillion in 2025, including $558 billion in the United States and $667 billion in the rest of the world. The estimate comes from Hardman & Co’s 2025 market calculation.[28]
Forecast & CAGR
IQVIA expects global medicine spending to exceed $2.6 trillion by 2030, with spending increasing by 5%–8% annually. Adjusted for population, global medicine-use growth is projected at 1.9% CAGR through 2030, compared with 2.7% on an unadjusted basis.[29]
Market share & regions
North America accounted for 54.7% of global prescription-medicine sales in 2025, while Europe represented 23.7%. The remaining 21.6% was distributed across China, Japan, other Asian markets, Latin America, Africa and Australia.[30]
Pricing
In Europe, distribution margins and value-added-tax rates vary significantly by country. EFPIA reports that, on average, approximately one-third of the retail price of a medicine represents the manufacturer’s share, with the remainder reflecting distribution, pharmacy margins, taxes and other components.[32]
Trends, drivers & challenges
Growth is being supported by new medicines, specialty therapies and rapid uptake of GLP-1 medicines for obesity, while pricing pressure, regulatory scrutiny and uneven regional growth remain constraints. Hardman & Co estimated underlying global pharmaceutical-market growth at 5.3% in 2025, excluding COVID-19-related products and foreign-exchange effects.[28][29]
Consumer behavior & competition
Medicine use is projected to grow 2.7% annually worldwide through 2030 before adjusting for population, but only 1.9% annually after population adjustment. Competition is increasingly shaped by specialty medicines, biologics, obesity treatments and the introduction of lower-cost biosimilars and generics.[29][31]
M&A
Pharmaceutical consolidation continues to attract regulatory intervention: in June 2026, the U.S. Federal Trade Commission required Aurobindo Pharma to divest four generic-drug products to complete its $250 million acquisition of Lannett Company, citing competition concerns in markets with few suppliers.[33]
Regulation
The FDA approved 46 novel drugs in 2025; 23, or 50%, received orphan-drug designation, and 39, or 85%, were approved on the first review cycle. By November 13, 2026, the FDA’s 2026 list had reached 50 novel-drug approvals.[31]
Latest news
The latest FDA approvals reported by November 13, 2026 included Klygefa, pimjetmi and Sunharbo, bringing the agency’s 2026 novel-drug total to 50. The 2026 approvals include treatments for generalized myasthenia gravis, tenosynovial giant-cell tumors and stroke-risk reduction.[31]

02 Ranking

Top 10 Companies in the Medicine Business Industry

The leading companies in the medicine business industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 18, 2026 · Next review December 18, 2026

Verdict

Eli Lilly and Company stands out for prescription-medicine revenue because its 2025 medicines revenue reached $65.2 billion, while Roche focuses on pharmaceuticals and diagnostics since it reported CHF47.7 billion in 2025 pharmaceutical sales.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in prescription medicines

    Eli Lilly and Company

    US

    Ranked #1 · 9.8 · Prescription medicines

    Why we picked it: Lilly’s prescription medicines business posted 44.7% revenue growth in 2025 and an operating margin of 40.4%.

  2. Leader in pharmaceuticals and diagnostics

    Roche

    CH

    Ranked #2 · 9.3 · Pharmaceuticals and diagnostics

    Why we picked it: Roche reported 7% revenue growth in 2025 and an R&D spend of 19.8% of revenue in pharmaceuticals.

  3. Leader in diabetes and obesity medicines

    Novo Nordisk

    DK

    Ranked #5 · 9.2 · Diabetes and obesity medicines

    Why we picked it: Novo Nordisk posted an operating margin of 41.3% in 2025 with R&D at 16.8% of revenue.

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the medicine business industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Eli Lilly and Company

Prescription medicines · US

9.8
2

Roche

Pharmaceuticals and diagnostics · CH

9.3
3

Novartis

Prescription medicines · CH

9.3
4

AstraZeneca

Prescription medicines · GB

9.2
5

Novo Nordisk

Diabetes and obesity medicines · DK

9.2
6

AbbVie

Innovative medicines, global · US

9.2
7

Merck

Prescription medicines and vaccines, global · US

8.9
8

Amgen

Biotechnology medicines, global · US

8.8
9

GSK

Biopharmaceuticals and vaccines, global · GB

8.6
10

Teva Pharmaceuticals

Generics, biosimilars and innovative medicines · IL

8.4

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 18, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 18). Top 10 companies in the medicine business industry. In Medicine Business Industry Statistics. Gitnux. https://gitnux.org/medicine-business-industry-statistics/#top-companies

report visual · Projection

Pharmaceutical industry production (Europe (EFPIA total))

Pharmaceutical industry production grew from €127.5B in 2000 to €440.0B in 2024.

127.5B EUR
Start
+5.3%
CAGR · 24y
440.4B EUR
Projected
20002024
source-verifiedefpia.eu2024

04 Statistics

Technology & AI

AI implementation shows up in near-term priorities. Seventy-three percent of respondents planned, piloted or deployed agentic AI initiatives in 2025.

AI and automation in the medicine business industry

  • 65% of European pharmaceutical manufacturers prioritized AI for predictive maintenance in their next 12 months of investment in 2025.[1]
  • 73% of respondents were planning, piloting or deploying agentic AI initiatives in pharmaceutical, biotechnology and bioengineering organizations in 2025.[2]
  • 17% of European pharmaceutical manufacturers reported currently using digital twins of their facilities in a survey conducted in December 2024–January 2025.[1]

05 Statistics

Market Intelligence

Outsourced development and manufacturing remain large and expanding. The CRO-and-CDMO market is projected to reach $459.33 billion by 2032 from $233.93 billion in 2024.

Market size and service revenue in the medicine business industry

  • $76.5 billion was the estimated 2023 global contract research organization market, covering discovery, pre-clinical and clinical outsourced pharmaceutical research services.[3]
  • $120.0 billion was the estimated 2023 global contract development and manufacturing organization market, covering outsourced pharmaceutical development and manufacturing services.[3]
  • $82.0 billion was estimated 2024 global revenue for contract research organization services, covering outsourced research for pharmaceutical, biotechnology and medical-device companies.[4]
  • $208 billion was the projected 2024 global pharma-services market, covering CRO, API/drug manufacturing and packaging services; the source classifies pharma services as outsourced drug-development, manufacturing and related support.[5]

Growth forecasts for the medicine business industry

  • The global pharmaceutical CRO-and-CDMO market is projected to reach $459.33 billion by 2032 from $233.93 billion in 2024, covering outsourced research, development, manufacturing, testing and packaging services.[6]
  • The global pharmaceutical CRO market is forecast for 2026–2034, with North America holding a 40% revenue share in 2025; the source covers discovery, laboratory, clinical, regulatory and data-management services.[7]
  • The global pharmaceutical contract-sales outsourcing market is projected to reach $13.19 billion by 2031 from $9.67 billion in 2025, implying a 5.32% CAGR during 2026–2031.[8]

Firm counts and size structure in the medicine business industry

  • More than 1,000 global CROs and CDMOs were identified in 2025 research, indicating a fragmented pharmaceutical contract-services supplier base spanning integrated and specialist providers.[3]
  • 569 providers were listed under contract and outsourcing services on PharmaCountry on September 21, 2026; the platform’s category includes pharmaceutical companies publishing at least one active service listing.[9]
  • 985 service providers were listed globally on PharmaCountry on September 21, 2026; the platform counts companies with at least one active pharmaceutical-service listing, not a complete industry census.[9]

Regional breakdown of the medicine business industry

  • North America accounted for 40% of global pharmaceutical CRO revenue in 2025, according to a market study covering discovery, laboratory, clinical, regulatory and data-management services.[7]
  • 14 pharmaceutical-service providers were listed for Canada on September 21, 2026, in PharmaCountry’s global supplier database; the count covers registered platform profiles, not the national industry census.[9]
  • 35 pharmaceutical-service providers were listed for Spain on September 21, 2026, in PharmaCountry’s global supplier database; the count covers registered platform profiles, not the national industry census.[9]

06 Statistics

Strategy & Growth

Deal activity tightened in physician-group consolidation. Like-for-like physician-group consolidation transactions fell by more than 50 deals, a 39% decline from 2023 to 2024.

M&A and consolidation in the medicine business industry

  • Like-for-like physician-group consolidation transactions in the United States fell by more than 50 deals, a 39% decline from 2023 to 2024.[10]
  • Professional Services represented 55.1% of U.S. healthcare-services transaction volume in 2024, the largest sector share in the review.[11]
  • Private-equity investors accounted for roughly 40% of total U.S. healthcare M&A deal volume in 2025, slightly below their 2024 share.[10]
  • 99 physician-practice acquisition transactions were announced in the United States in 2024, within healthcare professional services.[11]

07 Statistics

Operating Benchmarks

Provider-level operating measures vary by role mix. AMGA’s survey reported 60% of U.S. medical groups met or exceeded productivity goals in 2025.

Operating metrics used in the medicine business industry

  • $161,592 was median investment per provider in 2024, excluding overhead allocations, among system-affiliated U.S. medical groups surveyed by AMGA.[12]
  • 60% of U.S. medical groups reported that physician and advanced practice provider productivity in 2025 met or exceeded goals; 200 applicable responses were collected in March 2026.[13]
  • 45.9% of providers were advanced practice clinicians in 2024, up from 36.8% in 2020, among system-affiliated U.S. medical groups in AMGA’s operations and finance survey.[12]

08 Statistics

Clients & Demand

IT and claims outsourcing remain common in U.S. primary care and rehabilitation. HFS found 67% outsourced IT services in 2024 and 62% outsourced claims management.

Service penetration and outsourcing in the medicine business industry

  • 67% of U.S. primary-care and rehabilitation providers outsourced IT services in 2024; HFS surveyed 105 providers across six primary-care and rehabilitation specialties.[14]
  • 62% of U.S. primary-care and rehabilitation providers outsourced claims management in 2024; HFS surveyed 105 providers across six primary-care and rehabilitation specialties.[14]
  • 22.8%–24.8% was the estimated outsourcing penetration of the U.S. healthcare payer segment in 2024, measured as outsourced operations relative to segment healthcare expenditure.[15]
  • 40% of pharmaceutical and biotechnology CDMO decision-makers identified small-molecule API as the most outsourced product category in July 2024; the GLG survey covered 90 decision-makers across the U.S., Europe and Asia-Pacific.[16]

09 Statistics

Delivery & Operations

Clinic concentration patterns shape capacity planning. In 2024, 69.6% of U.S. office-based physicians worked at one location during a normal week.

Delivery capacity and installed base in the medicine business industry

  • 69.6% of U.S. office-based physicians worked at one location during a normal week in 2024, 20.7% at two locations and 9.5% at three or more locations.[17]
  • 58.1% of U.S. health-center physician capacity was supplied by family physicians, general practitioners and internists combined in 2024, based on 9,924.37 FTEs out of 15,755.73 physician FTEs.[18]
  • 18,393.12 FTE nurse practitioners, physician assistants and certified nurse midwives were available in U.S. federally supported health centers in 2024.[18]
  • 415,475 physicians worked in U.S. office-based medical practices in 2024, providing a national practitioner-capacity measure; the estimate covered 1,725 sampled physician records.[17]

10 Statistics

People & Workforce

Staffing constraints persist while compensation models diversify. In 2024, U.S. physician compensation increased 3.7% from 2023.

Employment and hiring in the medicine business industry

  • 38% of U.S. medical groups reported that physician vacancy time-to-fill increased during the year ending April 2025; 31% reported no change and 9% reported a reduction, from 248 responses.[13]
  • 56% of U.S. medical practices said medical-assistant hiring became more difficult during the year ending May 2026; 37% said it was unchanged and 7% said it became easier, from 297 responses.[13]
  • 2.95 million people were employed by U.S. offices of physicians excluding mental-health specialists in October 2024, according to the BLS Current Employment Statistics release; employment was 2.89 million in October 2023.[19]

Pay and labour costs in the medicine business industry

  • 70.5% of U.S. physicians received at least some salary-based compensation in 2024, while 55.0% received productivity-linked compensation and 39.0% received bonuses.[20]
  • More than 220,000 U.S. physicians and advanced-practice providers supplied 2024 compensation and productivity data for the 2025 MGMA Provider Compensation and Productivity Data Report.[13]
  • U.S. physician compensation increased 3.7% from 2023 to 2024, based on more than 37,000 physician responses collected in 2024.[21]

Skills and certification in the medicine business industry

  • 16% of U.S. medical groups used formal skill-gap assessments in March 2024, while 78% did not, from 345 applicable responses.[13]
  • 53% of U.S. medical-group leaders identified finding qualified candidates as their top staffing challenge for 2024, ahead of compensation and benefits at 29%, retention at 16% and other challenges at 2%.[13]
  • 56% of U.S. medical practices reported that medical-assistant hiring had become more difficult over the previous year in May 2026, citing shortages of qualified candidates and training-pipeline gaps; the poll received 297 applicable responses.[13]

Work models and delivery locations in the medicine business industry

  • 68.4% of physicians in U.S. private practices used telehealth in 2024, compared with 79.7% of physicians in hospital-owned practices.[20]
  • 71.4% of U.S. physicians reported that their practices used telehealth in 2024; 63.2% reported videoconferencing for patient visits and 20.3% reported remote patient monitoring.[20]
  • 60% of U.S. medical-group leaders planned to keep their overall share of remote and hybrid jobs steady during 2024; 22% planned an increase and 18% a decrease, from 334 responses.[13]

11 Statistics

Pricing

Hourly rates vary by specialty work and seniority. U.S. contract medical editing ran at $70–$90 per hour in 2024, including agency fees and W-2 costs.

Fees and price levels in the medicine business industry

  • U.S. medical communications contractors charged $70–$90 per hour for contract medical editing in 2024, including agency fees and W-2 costs, according to EPM Scientific.[22]
  • U.S. medical communications contractors charged $125–$155 per hour for medical-writer consulting in 2024, including agency fees and W-2 costs, according to EPM Scientific’s life-sciences staffing guide.[22]
  • Medical-device regulatory consulting services listed hourly rates of $200 for executive assistants, $275 for senior regulatory consultants and $350 for the president as of October 18, 2024.[23]
  • Mississippi’s 2025 health-care analysis contract set hourly fees of $391–$474 for managers through senior directors or scientists during March 2025–February 2026.[24]

12 Statistics

Finance

Ownership and employment mix continues to shift. In 2024, 23% of U.S. physicians were employed by corporate entities, up from 15% in 2019.

Ownership and investment in the medicine business industry

  • 23% of U.S. physicians were employed by corporate entities, including health insurers and private-equity firms, in 2024, up from 15% in 2019.[25]
  • 42.2% of U.S. physicians worked in private practice in 2024, down from 60.1% in 2012, according to the AMA Physician Practice Benchmark Survey.[25]
  • Private equity accounted for 65% of U.S. physician-practice acquisitions from 2019 through 2023, measured as the share of physicians whose acquired practices were bought by private-equity firms.[26]
  • 6.5% of U.S. physicians worked in private-equity-owned practices in 2024, up from 4.5% in 2022, based on a nationally representative AMA physician survey.[25]
  • At least 47% of U.S. physicians were employed by or affiliated with hospital systems in 2024, up from less than 30% in 2012.[25]

13 Statistics

Risk & Compliance

HIPAA notice and contracting timelines are tightly defined. Healthcare business associates must notify covered-entity clients within 60 calendar days after discovering a breach of unsecured protected health information.

Regulation and licensing in the medicine business industry

  • 90 days is the minimum website-posting period for substitute notice when a U.S. healthcare breach lacks current contact information for 10 or more affected people, under 45 CFR 164.404(d), as currently in force.[27]
  • Healthcare business associates cannot replace the required HIPAA contract with self-certification or third-party certification, under 45 CFR 164.504(e), as currently in force.[27]
  • A written business-associate contract is required for covered entities engaging U.S. healthcare business-service providers, under 45 CFR 164.504(e), as currently in force.[27]

Client data and confidentiality in the medicine business industry

  • 10 affected people is the threshold at which U.S. healthcare providers must use website or media substitute notice when contact information is insufficient or outdated, under 45 CFR 164.404(d).[27]
  • March 1 is the deadline for U.S. covered entities to report breaches affecting fewer than 500 people that were discovered during 2024, under the HIPAA Breach Notification Rule.[27]
  • 60 calendar days is the maximum period for a U.S. healthcare business associate to notify its covered-entity client after discovering a breach of unsecured protected health information, under 45 CFR 164.410.[27]

Incidents, safety and loss events in the medicine business industry

  • 106 large breach reports from U.S. healthcare business associates affected 206,921,071 people in 2024, representing 16% of 663 breaches affecting at least 500 people.[27]
  • 1,500 small breach reports from U.S. healthcare business associates affected 29,221 people in 2024, representing 2% of 74,299 breaches affecting fewer than 500 people.[27]
  • 534 hacking or information-technology breaches affected 241,582,022 people in U.S. healthcare in 2024, accounting for 81% of large breach reports and 99% of affected people.[27]

Key questions about the medicine business industry

What was the global pharmaceutical market size in 2025?
The global pharmaceutical market reached an estimated $1.225 trillion in 2025. Hardman & Co’s 2025 market calculation estimates $558 billion in the United States and $667 billion in the rest of the world.
How fast is medicine spending expected to grow to 2030?
IQVIA expects global medicine spending to exceed $2.6 trillion by 2030, increasing by 5%–8% annually. Adjusted for population, global medicine-use growth is projected at 1.9% CAGR through 2030.
Which companies lead the medicine business industry?
Eli Lilly and Company stands out for prescription-medicine revenue because its 2025 medicines revenue reached $65.2 billion, while Roche focuses on pharmaceuticals and diagnostics since it reported CHF47.7 billion in 2025 pharmaceutical sales.
Which technology shift is most prominent in recent pharma investment surveys?
European pharmaceutical manufacturers prioritized AI for predictive maintenance in their next 12 months of investment in 2025, with 65% reporting this focus. In the same period, 73% of respondents planned, piloted or deployed agentic AI initiatives.
How fragmented are contract services suppliers in pharma?
More than 1,000 global CROs and CDMOs were identified in 2025, indicating fragmentation in contract services. PharmaCountry listed 985 service providers globally on September 21, 2026, covering active pharmaceutical-service listings.
What does FDA novel-drug approval activity look like in 2025 and 2026?
In 2025, the FDA approved 46 novel drugs, with 23 receiving orphan-drug designation and 39 approved on the first review cycle. By November 13, 2026, the FDA’s 2026 list had reached 50 novel-drug approvals.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 18). Medicine Business Industry Statistics. Gitnux. https://gitnux.org/medicine-business-industry-statistics
MLA
Samuel Norberg. "Medicine Business Industry Statistics." Gitnux, 18 Nov 2026, https://gitnux.org/medicine-business-industry-statistics.
Chicago
Samuel Norberg. 2026. "Medicine Business Industry Statistics." Gitnux. https://gitnux.org/medicine-business-industry-statistics.